



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2018

---

**IKZF1 Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia**

Stanulla, Martin ; Dagdan, Elif ; Zaliova, Marketa ; et al ; Bourquin, Jean-Pierre ; Bornhauser, Beat

DOI: <https://doi.org/10.1200/JCO.2017.74.3617>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-162450>

Journal Article

Published Version

Originally published at:

Stanulla, Martin; Dagdan, Elif; Zaliova, Marketa; et al; Bourquin, Jean-Pierre; Bornhauser, Beat (2018). IKZF1 Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, 36(12):1240-1249.

DOI: <https://doi.org/10.1200/JCO.2017.74.3617>

# *IKZF1*<sup>plus</sup> Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Martin Stanulla, Elif Dagdan, Marketa Zaliova, Anja Möricke, Chiara Palmi, Giovanni Cazzaniga, Cornelia Eckert, Geertruy te Kronnie, Jean-Pierre Bourquin, Beat Bornhauser, Rolf Koehler, Claus R. Bartram, Wolf-Dieter Ludwig, Kirsten Bleckmann, Stefanie Groeneveld-Krentz, Denis Schewe, Stefanie V. Junk, Laura Hinze, Norman Klein, Christian P. Kratz, Andrea Biondi, Arndt Borkhardt, Andreas Kulozik, Martina U. Muckenthaler, Giuseppe Basso, Maria Grazia Valsecchi, Shai Izraeli, Britt-Sabina Petersen, Andre Franke, Petra Dörge, Doris Steinemann, Oskar A. Haas, Renate Panzer-Grümayer, Hélène Cavé, Richard S. Houlston, Gunnar Cario, Martin Schrappe, and Martin Zimmermann, for the TRANSCALL Consortium and the International BFM Study Group

Author affiliations and support information (if applicable) appear at the end of this article.

Published at [jco.org](http://jco.org) on March 2, 2018.

M. Stanulla, E.D., G.C., M. Schrappe, and M. Zimmermann contributed equally to this work.

Clinical trial information: NCT00430118.

Corresponding author: Martin Stanulla, MD, Department of Pediatric Hematology and Oncology, Hannover Medical School, Carl-Neuberg-Str 1, D-30625 Hannover, Germany; e-mail: stanulla.martin@mh-hannover.de.

© 2018 by American Society of Clinical Oncology

0732-183X/18/3612w-1240w/\$20.00

## ABSTRACT

### Purpose

Somatic deletions that affect the lymphoid transcription factor–coding gene *IKZF1* have previously been reported as independently associated with a poor prognosis in pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). We have now refined the prognostic strength of *IKZF1* deletions by analyzing the effect of co-occurring deletions.

### Patients and Methods

The analysis involved 991 patients with BCP ALL treated in the Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster (AIEOP-BFM) ALL 2000 trial with complete information for copy number alterations of *IKZF1*, *PAX5*, *ETV6*, *RB1*, *BTG1*, *EBF1*, *CDKN2A*, *CDKN2B*, *Xp22.33/Yp11.31* (PAR1 region; *CRLF2*, *CSF2RA*, and *IL3RA*), and *ERG*; replication of findings involved 417 patients from the same trial.

### Results

*IKZF1* deletions that co-occurred with deletions in *CDKN2A*, *CDKN2B*, *PAX5*, or PAR1 in the absence of *ERG* deletion conferred the worst outcome and, consequently, were grouped as *IKZF1*<sup>plus</sup>. The *IKZF1*<sup>plus</sup> group comprised 6% of patients with BCP ALL, with a 5-year event-free survival of 53 ± 6% compared with 79 ± 5% in patients with *IKZF1* deletion who did not fulfill the *IKZF1*<sup>plus</sup> definition and 87 ± 1% in patients who lacked an *IKZF1* deletion ( $P \leq .001$ ). Respective 5-year cumulative relapse incidence rates were 44 ± 6%, 11 ± 4%, and 10 ± 1% ( $P \leq .001$ ). Results were confirmed in the replication cohort, and multivariable analyses demonstrated independence of *IKZF1*<sup>plus</sup>. The *IKZF1*<sup>plus</sup> prognostic effect differed dramatically in analyses stratified by minimal residual disease (MRD) levels after induction treatment: 5-year event-free survival for MRD standard-risk *IKZF1*<sup>plus</sup> patients was 94 ± 5% versus 40 ± 10% in MRD intermediate- and 30 ± 14% in high-risk *IKZF1*<sup>plus</sup> patients ( $P \leq .001$ ). Corresponding 5-year cumulative incidence of relapse rates were 6 ± 6%, 60 ± 10%, and 60 ± 17% ( $P \leq .001$ ).

### Conclusion

*IKZF1*<sup>plus</sup> describes a new MRD-dependent very-poor prognostic profile in BCP ALL. Because current AIEOP-BFM treatment is largely ineffective for MRD-positive *IKZF1*<sup>plus</sup> patients, new experimental treatment approaches will be evaluated in our upcoming trial AIEOP-BFM ALL 2017.

*J Clin Oncol* 36:1240-1249. © 2018 by American Society of Clinical Oncology

## ASSOCIATED CONTENT



Appendix  
DOI: <https://doi.org/10.1200/JCO.2017.74.3617>



Data Supplement  
DOI: <https://doi.org/10.1200/JCO.2017.74.3617>

DOI: <https://doi.org/10.1200/JCO.2017.74.3617>

## INTRODUCTION

More than 80% of pediatric patients with B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) treated with modern protocols can achieve a long-term cure, but a significant proportion of

these patients still experience relapse and therapy-related toxicities.<sup>1,2</sup> Thus, the focus of therapy improvement for children with ALL—and any childhood cancer—is not only cure but also a minimization of both short- and long-term therapy-associated toxicities.<sup>3,4</sup> These goals can be achieved with better personalized adjustment

of therapy to the perceived risk of relapse.<sup>5,6</sup> At least 50% of relapses occur among patients classified as having standard or intermediate risk.<sup>7,8</sup> Although relapse-prone patients within these low-risk groups require more-effective therapy, a large number of the remaining children are most likely overtreated with toxic chemotherapy. Therefore, a pressing medical need exists for new prognostic markers to improve risk assessment and tailor treatment in this group of children with ALL.

Triggered by these clinical needs, technical advances in the field of genomic analyses have stimulated a large number of studies aimed at finding new biomarkers relevant for risk stratification.<sup>9-22</sup> A number of candidate markers have been identified and suggested as potentially useful for risk stratification in childhood ALL. To date, however, most of these genetic or genomic markers are not used regularly to support decision making on current clinical protocols for childhood ALL. General reasons for this lack of translation include the following: Initial studies have been conducted on small study populations only; study populations have been selected according to the availability of leukemic specimens for analysis; studies have been in patient populations that received heterogeneous and partly outdated treatments; conflicting results have been observed in various studies; and methodological differences in marker assessment and uncertainties about assay procedures exist. Furthermore, when assessed on up-to-date Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster (AIEOP-BFM) ALL protocols, the prognostic strength of many new high-risk markers is limited, which makes exposure to more-intensive and -toxic treatments difficult to justify for the potential benefit of a minority of patients identified by the marker.

The *IKZF1* gene encodes Ikaros, a zinc-finger transcription factor required for the development of all lymphoid lineages.<sup>23</sup> Somatic deletions of *IKZF1* have been described as a new high-risk marker in BCP ALL.<sup>24-31</sup> Recently, we and others demonstrated that activation of JAK-STAT signaling may enhance, whereas deletions of *ERG* can attenuate, the negative prognostic effect conferred by *IKZF1* deletions in BCP ALL.<sup>28,32-36</sup> The current study refines the prognostic strength of *IKZF1* deletions and characterizes a new very-poor prognostic subgroup termed *IKZF1*<sup>plus</sup>. *IKZF1*<sup>plus</sup> is a combination of previously described gene deletions and provides additional proof for the importance of moving from prognostic factors to prognostic profiles to sharpen the predictive strength of newly described genetic markers for integration into risk-adapted innovative treatment strategies for pediatric ALL.

## PATIENTS AND METHODS

### Sample Selection

The study included 991 patients with BCP ALL diagnosed between August 1999 and May 2009 who were enrolled into the international multicenter trial AIEOP-BFM ALL 2000 for the treatment of pediatric ALL in Germany and had complete information available for copy number alterations of *IKZF1*, *PAX5*, *ETV6*, *RBI*, *BTG1*, *EBF1*, *CDKN2A*, *CDKN2B*, Xp22.33/Yp11.31 (PAR1 region; *CRLF2*, *CSF2RA*, and *IL3RA* genes), and *ERG*.<sup>8,27,37</sup> For independent replication, 417 patients with BCP ALL treated in Italy in the same trial and with comparable genetic data available were analyzed (Fig 1).

In AIEOP-BFM ALL 2000, patients were stratified into three risk groups (standard, intermediate, and high). Risk group stratification

included minimal residual disease (MRD) analysis and required two MRD targets with sensitivities of  $\leq 1 \times 10^{-4}$ . MRD standard-risk (MRD-SR) patients were MRD negative on treatment days 33 and 78, and MRD high-risk (MRD-HR) patients had residual disease of  $\geq 5 \times 10^{-4}$  on treatment day 78. All remaining results were considered MRD intermediate risk (MRD-IR).<sup>37</sup> Although MRD analysis was the main stratification criterion in AIEOP-BFM ALL 2000, established high-risk parameters also were retained as follows: Patients with prednisone poor response (Table 1),  $\geq 5\%$  leukemic blasts in the bone marrow on day 33, or positivity for t(4;11) or its molecular equivalent (*MLL-AF4* gene fusion) were stratified into the high-risk group independent of their MRD results. Treatment included the use of standard drugs (eg, prednisone, vincristine, daunorubicin, L-asparaginase, cyclophosphamide, ifosfamide, cytarabine, 6-mercaptopurine, 6-thioguanine, and methotrexate) and in some of the patients, cranial irradiation and/or hematopoietic stem-cell transplantation (high-risk patients only). For analysis stratified according to National Cancer Institute (NCI) criteria, the definition of standard risk was an age at diagnosis of 1 year to younger than 10 years and an initial WBC count of  $< 50,000/\mu\text{L}$ ; NCI high-risk patients were 10 years and older and/or had an initial WBC of  $\geq 50,000/\mu\text{L}$ . The institutional review boards of Hannover Medical School and all participating centers approved the study. Informed consent was obtained in accordance with the Declaration of Helsinki.

### Molecular Genetic Analyses


Copy number alterations of *IKZF1*, *PAX5*, *ETV6*, *RBI*, *BTG1*, *EBF1*, *CDKN2A*, *CDKN2B*, and the Xp22.33/Yp11.31 region (PAR1 region; *CRLF2*, *CSF2RA*, and *IL3RA* genes; only deletion of *CSF2RA* and *IL3RA* and retention of the *CRLF2* probe associated with *P2RY8-CRLF2* fusion that leads to overexpression of *CRLF2* was regarded as PAR1 deletion in this study) were assessed by multiplex ligation-dependent probe amplification (MLPA) analyses (SALSA MLPA P335 ALL and P202-A1 *IKZF1* kits; MRC-Holland, Amsterdam, the Netherlands). *ERG* deletion detection was performed by a custom-made multiplex polymerase chain reaction assay as described previously.<sup>27,36</sup>

### Statistical Analysis

Differences in the distribution of individual parameters among patient subsets were analyzed using the  $\chi^2$  or Fisher's exact test for categorical variables and the Mann-Whitney *U* test for continuous variables. Event-free survival (EFS) was defined as the time from diagnosis to the date of last follow-up in complete remission (censored time) or first event. Events were resistance to therapy (nonresponse), relapse, secondary neoplasm, or death as a result of any cause. Failure to achieve remission as a result of early death or nonresponse was considered as event at time zero. The Kaplan-Meier method was used to estimate survival rates; differences were compared using the log-rank test (two-sided).<sup>38,39</sup> Cumulative incidence functions for competing events were estimated according to Kalbfleisch and Prentice<sup>40</sup> and were compared with Gray's test.<sup>41</sup> The Cox proportional hazards regression model was used to estimate hazard ratios and their 95% CIs for prognostic factors.<sup>42</sup> Furthermore, the classification and regression tree (CART) method was used to divide successively the *IKZF1*-deleted cohort into prognostic subgroups, which split a node into two subgroups using the covariate that best discriminated the cumulative incidence of relapse (CIR) on the basis of the lower limit of a one-sided 5% CI for the risk ratio.<sup>43,44</sup> The variable with the highest lower limit was used for the split. The process stopped when no covariate could split subgroups farther. Statistical analyses were conducted with SAS-PC 9.1 software (SAS Institute, Cary, NC). *P*  $\leq .05$  was considered statistically significant.

### Development of Prognostic *IKZF1* Deletion Profile

The prognostic effects of *IKZF1* deletion in combination with deletions in either *PAX5*, *ETV6*, *RBI*, *BTG1*, *EBF1*, *CDKN2A*, *CDKN2B*, or PAR1 were analyzed by separate assessments of CIRs for patients with



**Fig 1.** Flow diagram of patients in trial AIEOP-BFM (Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster) ALL 2000. ALL, acute lymphoblastic leukemia.

*IKZF1* deletion compared with those with *IKZF1* deletion co-occurring with one of the deletions mentioned. When numbers within a deletion subgroup exceeded 10 patients each, heterozygous and homozygous co-occurrence of a respective deletion with *IKZF1* deletion were addressed separately as well. When numbers were too low or the incidence of relapse was similar in patients with heterozygous and homozygous deletions, these groups were combined. Combinations that demonstrated a statistically significant higher CIR than *IKZF1* deletion alone in a single analysis qualified for integration into the prognostic deletion profile. Deletion selection for profile integration was further supported using CART analysis to identify deletions that best separate patients with *IKZF1* deletions into risk groups with adverse prognosis.<sup>43,44</sup>

## RESULTS

Initially, we analyzed the association between *IKZF1* deletion and other recurrent deletions observed in ALL by using MLPA data from 146 of the 991 patients whose ALL cells carried *IKZF1* deletions. Combined effects on relapse incidence were evaluated for deletions of *IKZF1* with either *PAX5*, *ETV6*, *RBI1*, *BTG1*, *EBF1*, *CDKN2A*, *CDKN2B*, or those that affected the PAR1 region and led to *CRLF2* overexpression (for definition of deletions that affect the PAR1 region, see Patients and Methods, under Molecular Genetic Analyses). *IKZF1* deletions that co-occurred with deletions in *CDKN2A*, *CDKN2B*, *PAX5*, or the PAR1 region conferred lower

EFS and higher CIRs than their respective negative counterparts (Appendix Fig A1, online only). For *CDKN2A*, a negative effect was detectable for heterozygous as well as homozygous deletions, whereas for *CDKN2B*, only homozygous deletions were of additive value (Appendix Fig A1). Consequently, all categories of *CDKN2A*, *CDKN2B*, *PAX5*, or the PAR1 region associated with a dismal prognosis in the context of *IKZF1* deletion were grouped. Deletion selection for grouping was further supported by CART analysis (Appendix Fig A2, online only). The additional markers assessed by MLPA (*ETV6*, *RBI1*, *BTG1*, and *EBF1*) and evaluated for combination effects were not included for refining *IKZF1* status because no significant influence on outcome was detectable (Appendix Fig A3, online only). Deletions of *ERG* attenuate the negative prognostic effect conferred by *IKZF1* deletions.<sup>35,36</sup> Within the group of BCP ALL that carry an *IKZF1* deletion and at least one additional unfavorable deletion in *CDKN2A*, *CDKN2B*, *PAX5*, or the PAR1 region, five patients demonstrated an *ERG* deletion as well. Thus, only minimal overlap was observed between the described aberration profile and deletion of *ERG*. Of note, none of these five patients experienced a relapse. The frequency and distribution of *IKZF1* and co-occurring deletions with prognostic effect are listed in Appendix Table A1 (online only). Consequently, the final definition of the new prognostic profile termed *IKZF1*<sup>plus</sup> was as follows: deletion of *IKZF1* that co-occurred with at least one additional deletion in *CDKN2A*, *CDKN2B* (homozygous


**Table 1.** Clinical Characteristics According to *IKZF1* Status in 991 Patients With B-Cell Precursor ALL Treated in Germany in Trial AIEOP-BFM ALL 2000

Characteristic	<i>IKZF1</i> Status, No. (%)			P*
	No <i>IKZF1</i> Deletion	<i>IKZF1</i> Deletion	<i>IKZF1</i> <sup>plus</sup>	
No. of patients	845	83	63	
Sex				
Male	447 (52.9)	44 (53.0)	30 (47.6)	
Female	398 (47.1)	39 (47.0)	32 (52.4)	.718
Age at diagnosis, years				
< 10	665 (78.7)	44 (53.0)	39 (61.9)	
≥ 10	180 (21.3)	39 (47.0)	24 (38.1)	< .001
Presenting WBC, count/ $\mu$ L				
< 10,000	383 (45.3)	29 (34.9)	10 (15.9)	
10,000 to < 50,000	308 (36.4)	38 (45.8)	23 (36.5)	
50,000 to < 100,000	93 (11.0)	9 (10.8)	17 (27.0)	
≥ 100,000	61 (7.2)	7 (8.4)	13 (20.6)	< .001
CNS positivity†				
No	788 (93.3)	77 (92.8)	55 (87.3)	
Yes	21 (2.5)	3 (3.6)	7 (11.1)	< .001
Unknown	36 (4.3)	3 (3.6)	1 (1.5)	
Hyperdiploidy‡				
No	457 (54.8)	53 (63.9)	48 (76.2)	
Yes	114 (13.5)	14 (16.9)	4 (6.4)	.091
Unknown	274 (32.4)	16 (19.3)	11 (17.5)	
<i>ETV6-RUNX1</i>				
Negative	587 (69.5)	77 (92.8)	61 (96.8)	
Positive	218 (25.8)	3 (3.6)	1 (1.6)	< .001
Unknown	40 (4.7)	3 (3.6)	1 (1.6)	
<i>MLL-AF4</i>				
Negative	840 (99.4)	83 (100)	63 (100)	
Positive	5 (0.6)	0 (0.0)	0 (0.0)	.649
Prednisone response§				
Good	790 (93.5)	68 (81.9)	56 (88.9)	
Poor	52 (6.2)	13 (15.7)	7 (11.1)	.001
Unknown	3 (0.4)	2 (2.4)	0 (0.0)	
MRD risk group				
Standard	338 (40.0)	15 (18.1)	19 (30.2)	
Intermediate	343 (40.6)	37 (44.6)	27 (42.9)	
High	28 (3.3)	20 (24.1)	10 (15.9)	< .001
Unknown	136 (16.1)	11 (13.3)	7 (11.1)	
Final risk group¶				
Standard	329 (38.9)	13 (15.7)	19 (30.2)	
Intermediate	438 (51.8)	45 (54.2)	33 (52.4)	
High	78 (9.2)	25 (30.1)	11 (17.5)	< .001
<i>GATA3</i> rs3824662 genotype				
GG	206 (24.4)	23 (27.7)	13 (20.6)	
TG	136 (16.1)	17 (20.5)	20 (31.7)	
TT	20 (2.4)	4 (4.8)	6 (9.5)	.029
Unknown	483 (57.2)	39 (47.0)	24 (38.1)	

NOTE. *IKZF1*<sup>plus</sup> definition: presence of *IKZF1* deletion and at least an additional deletion in *PAX5*, *CDKN2A*, *CDKN2B*, or *PAR1* in the absence of *ERG* deletion. *IKZF1* deletion definition: *IKZF1* deletion present but does not fulfill the *IKZF1*<sup>plus</sup> definition.  
Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; MRD, minimal residual disease.  
\* $\chi^2$  or Fisher's exact test that compares the groups with various *IKZF1* statuses.  
†Puncture nontraumatic, WBC count > 5/ $\mu$ L CSF with identifiable blasts.  
‡Defined by cytogenetics (> 50 chromosomes) or by flow cytometric analyses of the ratio of DNA content of leukemic G0/G1 cells to normal diploid lymphocytes ( $\geq 1.16$ ).  
§Good, < 1,000 leukemic blood blasts/ $\mu$ L on treatment day 8; poor,  $\geq 1,000/\mu$ L.  
||Standard risk, negative on treatment days 33 and 78; high risk, leukemic cell load  $\geq 5 \times 10^{-4}$  on treatment day 78; all other results intermediate risk.  
¶Treatment group (for definition see Patients and Methods, under Sample Selection).

deletion only), *PAX5*, or *PAR1* in the absence of *ERG* deletion. Characteristics of *IKZF1*<sup>plus</sup> compared with *IKZF1* deletions that did not fulfill the *IKZF1*<sup>plus</sup> definition (hereafter called *IKZF1* deletion) as well as no *IKZF1* deletion are listed in Table 1. Altogether, *IKZF1*<sup>plus</sup> comprised 6% of patients with BCP ALL. Specifically, patients with *IKZF1*<sup>plus</sup> positivity had higher WBC counts at diagnosis, were more often positive for CNS disease, and

were rarely *ETV6-RUNX1* positive. Their prednisone response and MRD kinetics were worse than for those who lacked any *IKZF1* deletion (Table 1). In an analysis that incorporated 498 patients with available information, the germline *GATA3* single-nucleotide variant rs3824662, which formerly was related to the risk of developing B-other or Philadelphia-like pediatric ALL, was associated with the *IKZF1*<sup>plus</sup> group (Table 1).<sup>45,46</sup>



**Fig 2.** Event-free survival (EFS) and cumulative incidence of relapse (CIR) at 5 years according to *IKZF1* status (no *IKZF1* deletion [*IKZF1* del], *IKZF1* del, *IKZF1*<sup>plus</sup>) in patients with B-cell precursor acute lymphoblastic leukemia (ALL) treated in trial AIEOP-BFM (Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin–Frankfurt–Muenster) ALL 2000. (A) EFS in 991 patients from the observational cohort recruited in Germany. (B) EFS in 417 patients from the replication cohort recruited in Italy. (C) CIR in the observational cohort. (D) CIR in the replication cohort. del, deletion.

In outcome analysis, *IKZF1*<sup>plus</sup> was associated with a 5-year EFS of 53 ± 6% compared with 79 ± 5% in patients with *IKZF1* deletion or 87 ± 1% in patients who lacked any *IKZF1* deletion (*IKZF1*<sup>plus</sup> v no *IKZF1* deletion,  $P \leq .001$ ; Fig 2A). The respective 5-year CIRs were 44 ± 6%, 11 ± 4%, and 10 ± 1% (*IKZF1*<sup>plus</sup> v no *IKZF1* deletion,  $P \leq .001$ ; Fig 2C). Appendix Fig A4 (online only) shows the poor prognostic effect of *IKZF1*<sup>plus</sup> in analyses stratified by NCI risk group and patients with high initial WBC counts of  $\geq 50,000/\mu\text{L}$  and  $\geq 100,000/\mu\text{L}$ . Multivariable analyses that included variables of clinical and prognostic relevance previously described in AIEOP-BFM ALL 2000<sup>37</sup> demonstrated independence of *IKZF1*<sup>plus</sup>—with *IKZF1*<sup>plus</sup> conferring the largest hazard ratio for relapse—and underscored its strong prognostic effect (Table 2).

We next used an independent cohort of 417 patients treated in AIEOP-BFM ALL 2000 in Italy who had the necessary genetic information available for confirmation of the negative prognostic effect of *IKZF1*<sup>plus</sup> (Appendix Table A2, online only). The 5-year EFS observed for *IKZF1*<sup>plus</sup> was 44 ± 12% compared with 74 ± 7% for *IKZF1* deletions or 85 ± 2% for no *IKZF1* deletions (*IKZF1*<sup>plus</sup> v no *IKZF1* deletion,  $P \leq .001$ ; Fig 2B). The respective 5-year CIRs were 44 ± 12%, 24 ± 7%, and 13 ± 2% (*IKZF1*<sup>plus</sup> v no *IKZF1* deletion,  $P = .001$ ; Fig 2D). Similar to the observation cohort, multivariable analyses in the validation cohort demonstrated independence of *IKZF1*<sup>plus</sup> (Appendix Table A3, online only).

We have previously demonstrated that MRD risk group (for definition, see Patients and Methods, under Sample Selection) is

**Table 2.** Estimated HRs From the Multivariable Cox Proportional Hazards Model on Event-Free Survival and Hazard of Relapse in Patients With B-Cell Precursor ALL From Trial AIEOP-BFM ALL 2000

Variable	Event			Relapse		
	HR	95% CI	P	HR	95% CI	P
IKZF1 <sup>plus</sup> *	2.62	1.41 to 4.86	.002	4.00	1.91 to 8.37	< .001
IKZF1 deletion†	1.03	0.60 to 1.76	.928	0.85	0.44 to 1.67	.639
ETV6-RUNX1 positivity‡	0.97	0.60 to 1.56	.903	1.03	0.62 to 1.70	.908
MRD standard risk§	0.49	0.31 to 0.77	.002	0.42	0.26 to 0.68	< .001
MRD high risk¶	3.42	2.07 to 5.65	< .001	2.04	1.10 to 3.81	.024
Slow early MRD response	2.70	1.64 to 4.44	< .001	2.69	1.60 to 4.53	< .001
Poor prednisone response¶¶	1.13	0.68 to 1.88	.633	0.94	0.51 to 1.72	.840
Presenting WBC# count ≥ 100,000/μL	2.36	1.49 to 3.74	< .001	2.59	1.56 to 4.28	< .001

Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; HR, hazard ratio; MRD, minimal residual disease.

\*Presence of IKZF1 deletion and at least an additional deletion in *PAX5*, *CDKN2A*, *CDKN2B*, or *PAR1* in the absence of *ERG* deletion. HR compared with patients who lacked an *IKZF1* deletion.

†IKZF1 deletion present but does not fulfill the IKZF1<sup>plus</sup> definition. HR compared with patients who lacked an *IKZF1* deletion.

‡Compared with *ETV6-RUNX1* negativity.

§MRD standard risk, negative on treatment days 33 and 78; MRD high risk, leukemic cell load ≥ 5 × 10<sup>-4</sup> on treatment day 78; all other results MRD intermediate risk. HR compared with other MRD groups.

¶MRD ≥ 5 × 10<sup>-4</sup> on treatment day 33 and positivity of < 5 × 10<sup>-4</sup> on treatment day 78. HR compared with MRD intermediate-risk patients with no slow early response.

¶¶Leukemic blasts ≥ 1,000/μL in the peripheral blood on treatment day 8. HR compared with patients with < 1,000/μL leukemic blasts.

#HR compared with patients with presenting WBC counts < 100,000/μL.


the strongest prognostic factor in our protocol.<sup>37</sup> Therefore, we assessed the prognostic effect of IKZF1<sup>plus</sup> in the context of treatment response and treatment intensity. Unexpected dramatic differences among MRD risk groups were detected in these analyses: The 5-year EFS for MRD-SR IKZF1<sup>plus</sup> patients was 94 ± 5% compared with 40 ± 10% in MRD-IR and 30 ± 14% in MRD-HR IKZF1<sup>plus</sup> patients; the corresponding 5-year CIRs were 6 ± 6%, 60 ± 10%, and 60 ± 17%. Figure 3 demonstrates these results for IKZF1<sup>plus</sup> compared with IKZF1 deletions and no IKZF1 deletions. When the type and number of deletions in IKZF1<sup>plus</sup> were assessed by MRD risk group to explain the observed differential prognostic effect (Appendix Tables A4 and A5, online only), neither obvious differences in type nor significant differences in number of deletions (P = .750) were detected among the MRD risk groups. Finally, we analyzed whether we could detect changes in aberration profiles of IKZF1<sup>plus</sup> samples from initial diagnosis to relapse. For this purpose, we compared 14 samples with MLPA analyses from both time points and did not identify recurrent profile changes (Appendix Table A6, online only). Taken together, IKZF1<sup>plus</sup> conferred an extremely high risk of relapse, specifically to MRD-IR and MRD-HR patients.

## DISCUSSION

We define a new and powerful prognostic profile, IKZF1<sup>plus</sup>, for pediatric ALL treated with BFM therapy-based clinical protocols. The use of IKZF1 deletion in combination with specific additional single genetic deletions provides an independent strong molecular stratification marker in addition to MRD measurements. The extremely poor outcome of patients treated by either intermediate- or high-intensity chemotherapy suggests that MRD-IR and MRD-HR IKZF1<sup>plus</sup> patients should be enrolled in clinical trials that incorporate and evaluate experimental therapies.

Research on the clinical and biologic aspects of ALL has identified numerous prognostic factors used in modern clinical protocols to stratify patients according to their probability of treatment failure into risk groups of various treatment intensities (eg, standard/low, intermediate, high).<sup>1,2</sup> During the past two decades, molecular monitoring of MRD in AIEOP-BFM studies has become the most important prognostic factor.<sup>8,37</sup> However, although a poor early response to therapy as characterized by our MRD-HR definition predicts treatment failure and defines a true high-risk patient population, the majority of recurrences are still observed in the large group of MRD-IR patients. In AIEOP-BFM ALL 2000, 69% of BCP ALL relapses occurred in these patients, which exemplifies that for a majority of patients with disease recurrence, the precedent treatment stratification strategy does not adequately reflect their actual risk of relapse.<sup>8,37</sup> Consequently, current treatment stratification still needs improvement to lead to a more-precise early characterization of the patient at true risk of relapse. Upfront identification of these patients is essential in future clinical trials for optimal therapy early on and for high-risk patients, the timely introduction of innovative treatment options, such as immunotherapy.<sup>47</sup> IKZF1<sup>plus</sup> represents a simple pragmatic approach to addressing this dilemma: The group comprised approximately 6% of patients with BCP ALL, which accounts for approximately 25% of relapses; the majority of the relapses occurred in MRD-IR patients. Therefore, the use of this new biomarker is directly applicable to clinical practice to improve risk stratification of patients treated in AIEOP-BFM ALL trials.

Several studies have linked IKZF1 deletions to an unfavorable clinical outcome of BCP ALL in various treatment protocols, including those that used risk stratification guided by MRD monitoring.<sup>24-36,48-51</sup> As a consequence, international study groups have included IKZF1 deletion status in their high-risk treatment stratification strategies for patients with BCP ALL.<sup>48,49</sup> However, other study groups, including AIEOP-BFM, currently do not



**Fig 3.** Event-free survival (EFS) and cumulative incidence of relapse (CIR) at 5 years according to *IKZF1* status (no *IKZF1* deletion [*IKZF1* del], *IKZF1* del, *IKZF1*<sup>plus</sup>) in 837 patients with B-cell precursor acute lymphoblastic leukemia (ALL) with available minimal residual disease (MRD) data treated in trial AIEOP-BFM (Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster) ALL 2000. MRD standard-risk (MRD-SR) patients were MRD negative on treatment days 33 and 78; MRD high-risk (MRD-HR) patients had leukemic cell loads of  $\geq 5 \times 10^{-4}$  on treatment day 78; and all other results were classified as MRD intermediate risk (MRD-IR). For exact definitions, see Patients and Methods, under Sample Selection. (A) EFS in MRD-SR patients. (B) EFS in MRD-IR patients. (C) EFS in MRD-HR patients. (D) CIR in MRD-SR patients. (E) CIR in MRD-IR patients. (F) CIR in MRD-HR patients. del, deletion.



follow this strategy because the prognostic effect of *IKZF1* deletions is judged as not profound enough to justify exposure to the toxic adverse effects of high-risk treatment of a majority of actual intermediate-risk patients not in need of treatment intensification.<sup>27,33,52</sup> By the definition of *IKZF1*<sup>plus</sup>, we refined the prognostic strength of *IKZF1* deletions by describing a very-poor prognostic *IKZF1* deletion-associated genetic aberration profile that now, in combination with MRD analyses, justifies clinical implementation as a high-risk stratification criterion in frontline AIEOP-BFM trials for the treatment of ALL.

Despite these promises, there are limitations with our approach. First, besides polymerase chain reaction analysis for *ERG* deletions, our study used MLPA-based assessment of leukemic copy number aberrations. This assay has a limited sensitivity to detect less-abundant subclonal lesions (< 30%). However, the prognostic significance of these subclonal lesions is unclear, and the relevance of their exact quantification currently is a matter of debate.<sup>49,53</sup> Second, although we initiated our analysis with 991 patients, we may have missed additional prognostically relevant deletions as a result of a lack of power. In this context, continued analyses, including the pooling of copy number variation data across study groups, will secure identification of additional combinations with prognostic effect. Third, in our simple approach, we only incorporated the data available to us, which led to a restricted view by potentially excluding additional relevant information. The capture of broader information by more-comprehensive genomic techniques could further expand and strengthen the *IKZF1*<sup>plus</sup> profile. Fourth, we lacked information on other relevant prognostic subgroups. For example, *IKZF1* deletions frequently are found in Philadelphia-like and *BCR-ABL1*-like ALL, two related subgroups characterized by tyrosine kinases or cytokine receptor activation. Indeed, Roberts et al<sup>54</sup> described a negative prognostic effect for *IKZF1* deletions in Philadelphia-like ALL. In contrast, a similar effect could not be observed by van der Veer et al<sup>48</sup> when analyzing the role of *IKZF1* deletions in *BCR-ABL1*-like ALL. Finally, because of a lack of systematic assessment, we were not able to compare our approach with other existing ones that integrated *IKZF1* deletion status with molecular and/or conventional diagnostic genetic information with or without MRD data.<sup>33,49,50</sup> For example, we did not routinely analyze *IGH-CRLF2* fusions in our cohort and, therefore, cannot judge their possible prognostic significance alone or in the context of *IKZF1* deletion. Future, more-comprehensive prospective studies will need to determine the potential interactions of *IKZF1*<sup>plus</sup> with kinase-activating and other poor prognosis genetic aberrations in our trials.

One intriguing observation related to *IKZF1*<sup>plus</sup> is the strong dependence of its prognostic effect on MRD. In MRD-SR patients with no measurable MRD after induction, treatment outcome was not negatively affected by the presence of *IKZF1*<sup>plus</sup>, whereas patients with measurable MRD (MRD-IR, MRD-HR) faced a 10-fold higher relapse rate. Previous studies, including ours, described an association of *IKZF1* deletion and MRD in ALL. However, the effects observed in these studies were not comparable with regard to the dramatic extent observed in the current study,<sup>27,33,52</sup> or studies were performed under different conditions with regard to MRD assessment, risk stratification, or treatment.<sup>46,51,55</sup> Hypothetical explanations for the effect

observed in the current study could be different distributions of either additional leukemic aberrations or underlying hereditary factors in MRD-SR compared with MRD-IR and MRD-HR patients. Future research efforts will need to discover the mechanism that underlies the differential prognostic effect of *IKZF1*<sup>plus</sup> in various MRD risk groups.

With speculation on the characteristics that unify *IKZF1*<sup>plus</sup> patients as a subgroup, the ALL risk-conferring *GATA3* single-nucleotide variant rs3824662<sup>45,46</sup> was found to be enriched within *IKZF1*<sup>plus</sup> patients. This may point to a common hereditary background in these patients, which needs additional characterization.

In conclusion, we have integrated molecular genetic data with MRD data into a single combined classification that will be used to refine treatment stratification and guide innovative but still costly therapeutic applications in our upcoming trial AIEOP-BFM ALL 2017 for frontline treatment of pediatric ALL. To go beyond current risk stratification strategies, additional research on the biologic basis of our observations is needed and will be helpful in guiding the development of more-targeted and less-toxic innovative therapies for children and adolescents with ALL.

#### AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at [jco.org](http://jco.org).

#### AUTHOR CONTRIBUTIONS

**Conception and design:** Martin Stanulla, Martina U. Muckenthaler, Gunnar Cario, Martin Schrappe, Martin Zimmermann

**Financial support:** Martin Stanulla, Andrea Biondi, Giuseppe Basso, Renate Panzer-Grümayer, Martin Schrappe

**Administrative support:** Andrea Biondi, Giuseppe Basso, Renate Panzer-Grümayer, Martin Schrappe, Martin Stanulla

**Provision of study materials or patients:** Andrea Biondi, Giuseppe Basso, Gunnar Cario, Cornelia Eckert, Richard S. Houlston, Renate Panzer-Grümayer, Martin Schrappe, Martin Stanulla

**Collection and assembly of data:** Martin Stanulla, Elif Dagdan, Marketa Zaliova, Anja Möricke, Chiara Palmi, Giovanni Cazzaniga, Cornelia Eckert, Geertruy te Kronnie, Rolf Koehler, Claus R. Bartram, Wolf-Dieter Ludwig, Kirsten Bleckmann, Stefanie Groeneveld-Krentz, Denis Schewe, Andrea Biondi, Andreas Kulozik, Giuseppe Basso, Maria Grazia Valsecchi, Britt-Sabrina Petersen, Andre Franke, Petra Dörge, Doris Steinemann, Oskar A. Haas, Renate Panzer-Grümayer, Hélène Cavé, Richard S. Houlston

**Data analysis and interpretation:** Martin Stanulla, Elif Dagdan, Marketa Zaliova, Anja Möricke, Giovanni Cazzaniga, Cornelia Eckert, Geertruy te Kronnie, Jean-Pierre Bourquin, Beat Bornhauser, Stefanie V. Junk, Laura Hinze, Norman Klein, Christian P. Kratz, Andrea Biondi, Arndt Borkhardt, Andreas Kulozik, Giuseppe Basso, Maria Grazia Valsecchi, Shai Izraeli, Renate Panzer-Grümayer, Hélène Cavé, Gunnar Cario, Martin Schrappe, Martin Zimmermann

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

## REFERENCES

1. Pui CH, Yang JJ, Hunger SP, et al: Childhood acute lymphoblastic leukemia: Progress through collaboration. *J Clin Oncol* 33:2938-2948, 2015
2. Vrooman LM, Silverman LB: Treatment of childhood acute lymphoblastic leukemia: Prognostic factors and clinical advances. *Curr Hematol Malig Rep* 11:385-394, 2016
3. Lund B, Åsberg A, Heyman M, et al: Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. *Pediatr Blood Cancer* 56:551-559, 2011
4. Oeffinger KC, Mertens AC, Sklar CA, et al: Chronic health conditions in adult survivors of childhood cancer. *N Engl J Med* 355:1572-1582, 2006
5. Hunger SP, Mullighan CG: Redefining ALL classification: Toward detecting high-risk ALL and implementing precision medicine. *Blood* 125:3977-3987, 2015
6. Chiaretti S, Gianfelici V, O'Brien SM, et al: Advances in the genetics and therapy of acute lymphoblastic leukemia. *Am Soc Clin Oncol Educ Book* 35:e314-e322, 2016
7. Vora A, Goulden N, Wade R, et al: Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): A randomised controlled trial. *Lancet Oncol* 14:199-209, 2013
8. Möricke A, Zimmermann M, Valsecchi MG, et al: Dexamethasone vs prednisone in induction treatment of pediatric ALL: Results of the randomized trial AIEOP-BFM ALL 2000. *Blood* 127:2101-2112, 2016
9. Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. *Science* 286:531-537, 1999
10. Yeoh EJ, Ross ME, Shurtleff SA, et al: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. *Cancer Cell* 1:133-143, 2002
11. Lugthart S, Cheok MH, den Boer ML, et al: Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. *Cancer Cell* 7:375-386, 2005
12. Cario G, Izraeli S, Teichert A, et al: High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. *J Clin Oncol* 25:4813-4820, 2007
13. Moorman AV, Richards SM, Robinson HM, et al: Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). *Blood* 109:2327-2330, 2007
14. Mullighan CG, Goorha S, Radtke I, et al: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature* 446:758-764, 2007
15. Strefford JC, Worley H, Barber K, et al: Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. *Oncogene* 26:4306-4318, 2007
16. Davidsson J, Paulsson K, Lindgren D, et al: Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: Presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations. *Leukemia* 24:924-931, 2010
17. Irving J, Matheson E, Minto L, et al: Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukaemia and confer sensitivity to MEK inhibition. *Blood* 124:3420-3430, 2014
18. Loh ML, Zhang J, Harvey RC, et al: Tyrosine kinase sequencing of pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group TARGET Project. *Blood* 121:485-488, 2013
19. Wesolowska-Andersen A, Borst L, Dalgaard MD, et al: Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients. *Leukemia* 29:297-303, 2015
20. Carroll WL, Raetz E, Meyer J: State of the art discovery with tumor profiling in pediatric oncology. *Am Soc Clin Oncol Educ Book* 35:e601-e607, 2015
21. Fischer U, Forster M, Rinaldi A, et al: Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. *Nat Genet* 47:1020-1029, 2015
22. Paulsson K, Lilljebjörn H, Biloglav A, et al: The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. *Nat Genet* 47:672-676, 2015
23. Georgopoulos K, Bigby M, Wang JH, et al: The Ikaros gene is required for the development of all lymphoid lineages. *Cell* 79:143-156, 1994
24. Mullighan CG, Su X, Zhang J, et al: Deletion of *IKZF1* and prognosis in acute lymphoblastic leukemia. *N Engl J Med* 360:470-480, 2009
25. Martinelli G, Iacobucci I, Storlazzi CT, et al: *IKZF1* (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: A GIMEMA AL WP report. *J Clin Oncol* 27:5202-5207, 2009
26. Kuiper RP, Waanders E, van der Velden VH, et al: *IKZF1* deletions predict relapse in uniformly treated pediatric precursor B-ALL. *Leukemia* 24:1258-1264, 2010
27. Dörge P, Meissner B, Zimmermann M, et al: *IKZF1* deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. *Haematologica* 98:428-432, 2013
28. Yamashita Y, Shimada A, Yamada T, et al: *IKZF1* and *CRLF2* gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia. *Pediatr Blood Cancer* 60:1587-1592, 2013
29. Ofverholm I, Tran AN, Heyman M, et al: Impact of *IKZF1* deletions and *PAX5* amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols. *Leukemia* 27:1936-1939, 2013
30. Olsson L, Castor A, Behrendtz M, et al: Deletions of *IKZF1* and *SPRED1* are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. *Leukemia* 28:302-310, 2014
31. van der Veer A, Zaliava M, Mottadelli F, et al: *IKZF1* status as a prognostic feature in BCR-ABL1-positive childhood ALL. *Blood* 123:1691-1698, 2014
32. Mullighan CG, Zhang J, Harvey RC, et al: JAK mutations in high-risk childhood acute lymphoblastic leukemia. *Proc Natl Acad Sci U S A* 106:9414-9418, 2009
33. Chen IM, Harvey RC, Mullighan CG, et al: Outcome modeling with *CRLF2*, *IKZF1*, *JAK*, and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group study. *Blood* 119:3512-3522, 2012
34. Olsson L, Albitar F, Castor A, et al: Cooperative genetic changes in pediatric B-cell precursor acute lymphoblastic leukemia with deletions or mutations of *IKZF1*. *Genes Chromosomes Cancer* 54:315-325, 2015
35. Clappier E, Auclerc MF, Rapon J, et al: An intragenic *ERG* deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent *IKZF1* deletions. *Leukemia* 28:70-77, 2014
36. Zaliava M, Zimmermann O, Dörge P, et al: *ERG* deletion is associated with *CD2* and attenuates the negative impact of *IKZF1* deletion in childhood acute lymphoblastic leukemia. *Leukemia* 28:182-185, 2014
37. Conter V, Bartram CR, Valsecchi MG, et al: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. *Blood* 115:3206-3214, 2010
38. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 53:457-481, 1958
39. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. *Cancer Chemother Rep* 50:163-170, 1966
40. Kalbfleisch JD, Prentice RL: *The Statistical Analysis of Failure Time Data* (ed 1). New York, NY, Wiley, 1980, p 163
41. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. *Ann Stat* 16:1141-1154, 1988
42. Cox DR: Regression models and life tables. *J R Stat Soc [Ser A]* 34:187-220, 1972
43. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc* 94:496-509, 1999
44. Schmoor C, Ulm K, Schumacher M: Comparison of the Cox model and the regression tree procedure in analysing a randomized clinical trial. *Stat Med* 12:2351-2366, 1993
45. Migliorini G, Fiege B, Hosking FJ, et al: Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. *Blood* 122:3298-3307, 2013
46. Perez-Andreu V, Roberts KG, Harvey RC, et al: Inherited *GATA3* variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. *Nat Genet* 45:1494-1498, 2013
47. Jabbour E, O'Brien S, Ravandi F, et al: Monoclonal antibodies in acute lymphoblastic leukemia. *Blood* 125:4010-4016, 2015
48. van der Veer A, Waanders E, Pieters R, et al: Independent prognostic value of BCR-ABL1-like signature and *IKZF1* deletion, but not high *CRLF2* expression, in children with B-cell precursor ALL. *Blood* 122:2622-2629, 2013
49. Moorman AV, Enshaei A, Schwab C, et al: A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. *Blood* 124:1434-1444, 2014
50. Clappier E, Gardel N, Bakkus M, et al: *IKZF1* deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: Results of the EORTC Children's Leukemia Group study 58951. *Leukemia* 29:2154-2161, 2015
51. Waanders E, van der Velden VH, van der Schoot CE, et al: Integrated use of minimal residual disease classification and *IKZF1* alteration status

accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. *Leukemia* 25:254-258, 2011

52. Palmi C, Valsecchi MG, Longinotti G, et al: What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? *Haematologica* 98:1226-1231, 2013

53. Morak M, Attarbaschi A, Fischer S, et al: Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL. *Blood* 120:5134-5142, 2012

54. Roberts KG, Li Y, Payne-Turner D, et al: Targetable kinase-activating lesions in Ph-like acute

lymphoblastic leukemia. *N Engl J Med* 371:1005-1015, 2014

55. Hinze L, Möricke A, Zimmermann M, et al: Prognostic impact of *IKZF1* deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95. *Leukemia* 31:1840-1842, 2017

### **Affiliations**

**Martin Stanulla, Elif Dagdan, Stefanie V. Junk, Laura Hinze, Norman Klein, Christian P. Kratz, Petra Dörge, Doris Steinemann, and Martin Zimmermann**, Hannover Medical School; **Petra Dörge**, German Center for Infection Research, Hannover; **Anja Möricke, Kirsten Bleckmann, Denis Schewe, Gunnar Cario, and Martin Schrappe**, University Hospital Schleswig-Holstein; **Britt-Sabina Petersen and Andre Franke**, Kiel University, Kiel; **Cornelia Eckert and Stefanie Groeneveld-Krentz**, Charité University Hospital; **Wolf-Dieter Ludwig**, HELIOS-Clinic Berlin-Buch, Berlin; **Rolf Koehler, Claus R. Bartram, Andreas Kulozik, and Martina U. Muckenthaler**, University of Heidelberg, Heidelberg; **Arndt Borkhardt**, Heinrich-Heine University, Düsseldorf, Germany; **Marketa Zaliouva**, Charles University and University Hospital Motol, Prague, Czech Republic; **Chiara Palmi, Giovanni Cazzaniga, and Andrea Biondi**, Azienda Ospedaliera San Gerardo; **Maria Grazia Valsecchi**, University of Milano-Bicocca, Monza; **Geertruy te Kronnie and Giuseppe Basso**, University of Padova, Padua, Italy; **Jean-Pierre Bourquin and Beat Bornhauser**, University Children's Hospital Zurich, Zurich, Switzerland; **Shai Izraeli**, Sheba Medical Center Tel-Hashomer and Tel Aviv University, Tel Aviv, Israel; **Oskar A. Haas and Renate Panzer-Grümayer**, St Anna Kinderkrebsforschung and Medical University Vienna, Vienna, Austria; **Hélène Cavé**, Robert Debré Hospital and Paris-Diderot University, Paris, France; and **Richard S. Houlston**, The Institute of Cancer Research, London, United Kingdom.

### **Support**

Supported by ERA-NET TRANSCAN/European Commission under the Seventh Framework Programme, Madeleine-Schickedanz-Kinderkrebsstiftung, Deutsche Krebshilfe, Verein für krebskranke Kinder Hannover eV, Deutsche José Carreras Leukämie-Stiftung, the Grant Agency of the Czech Republic (GJ15-06049Y to M. Zaliouva), and the Austrian Science Fund (FWF I1226-B19 to R.P.-G.). A.B. was supported by the German Consortium of Translational Cancer Research and Tour of Hope (cycling for children with cancer).

## **ASCO's Journal of Global Oncology**

This online-only, open access journal fills a growing need for high-quality literature on the array of challenges that health care professionals in resource-limited settings face in caring for patients with cancer and in conducting research. Topics covered include:

- Cancer treatment and diagnosis
- Palliative and supportive care
- Prevention
- Barriers to care
- Epidemiology
- Health policy

Article types that will be considered include original reports, reviews, commentaries, correspondence, special articles, case reports, and editorials.

Submit your article today at [submitjgo.ascopubs.org](http://submitjgo.ascopubs.org)

**jgo**  
Journal of  
Global Oncology®

**ASCO**  
AMERICAN SOCIETY OF CLINICAL ONCOLOGY

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

**IKZF1<sup>plus</sup> Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/jco/site/ife](http://ascopubs.org/jco/site/ife).

**Martin Stanulla**

**Honoraria:** Baxalta

**Elif Dagdan**

No relationship to disclose

**Marketa Zaliova**

No relationship to disclose

**Anja Möricke**

**Honoraria:** Baxalta, Jazz Pharmaceuticals

**Travel, Accommodations, Expenses:** Jazz Pharmaceuticals

**Chiara Palmi**

No relationship to disclose

**Giovanni Cazzaniga**

No relationship to disclose

**Cornelia Eckert**

No relationship to disclose

**Geertruy te Kronnie**

No relationship to disclose

**Jean-Pierre Bourquin**

**Honoraria:** Amgen

**Beat Bornhauser**

No relationship to disclose

**Rolf Koehler**

No relationship to disclose

**Claus R. Bartram**

No relationship to disclose

**Wolf-Dieter Ludwig**

No relationship to disclose

**Kirsten Bleckmann**

**Travel, Accommodations, Expenses:** Jazz Pharmaceuticals

**Stefanie Groeneveld-Krentz**

No relationship to disclose

**Denis Schewe**

No relationship to disclose

**Stefanie V. Junk**

No relationship to disclose

**Laura Hinze**

No relationship to disclose

**Norman Klein**

No relationship to disclose

**Christian P. Kratz**

No relationship to disclose

**Andrea Biondi**

No relationship to disclose

**Arndt Borkhardt**

No relationship to disclose

**Andreas Kulozik**

No relationship to disclose

**Martina U. Muckenthaler**

**Honoraria:** Novartis, Silence Therapeutics

**Consulting or Advisory Role:** Merck

**Research Funding:** Novartis, Silence Therapeutics

**Giuseppe Basso**

No relationship to disclose

**Maria Grazia Valsecchi**

No relationship to disclose

**Shai Izraeli**

**Speakers' Bureau:** prIME Oncology

**Britt-Sabrina Petersen**

No relationship to disclose

**Andre Franke**

No relationship to disclose

**Petra Dörge**

No relationship to disclose

**Doris Steinemann**

No relationship to disclose

**Oskar A. Haas**

No relationship to disclose

**Renate Panzer-Grümayer**

No relationship to disclose

**Hélène Cavé**

**Honoraria:** Bristol-Myers Squibb

**Consulting or Advisory Role:** Roche

**Richard S. Houlston**

No relationship to disclose

**Gunnar Cario**

No relationship to disclose

**Martin Schrappe**

**Honoraria:** prIME Oncology

**Research Funding:** Novartis, Sigma Tau Pharmaceuticals, Baxter, Medac


**Martin Zimmermann**

No relationship to disclose


***Acknowledgment***

Dedicated to the memory of Prof Enno Kleihauer, a brilliant pediatrician and hematologist, who died in June 2017 shortly before his 90th birthday. We thank all participants and personnel involved in trial AIEOP-BFM ALL 2000.


Appendix



**Fig A1.** Cumulative relapse incidence (CIR) at five years in B-cell precursor ALL patients treated on trial AIEOP-BFM (Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster) ALL 2000 according to *IKZF1* status alone or in combination with (A) heterozygous or homozygous *CDKN2A* deletion, (B) heterozygous or homozygous *PAX5* deletion, (C) *PAR1* deletion, (D) homozygous *CDKN2B* deletion. (E) and (F) show *CDKN2A* and *CDKN2B* wild-type, heterozygous and homozygous deletions separately. (\*) Fourteen patients with heterozygous (het) *PAX5* deletion, one patient with homozygous (hom) *PAX5* deletion (del). pCIR, estimated cumulative incidence of relapse.




**Fig A2.** Classification and regression tree analysis of sequentially subclassified patients by genetic data from multiplex ligation-dependent probe amplification analysis that included *PAX5*, *ETV6*, *RB1*, *BTG1*, *EBF1*, *CDKN2A*, *CDKN2B*, or *PAR1* for the 146 patients with *IKZF1* deletion (del) from AIEOP-BFM (Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster) Acute Lymphoblastic Leukemia (ALL) 2000 for whom these data were available. The most discriminatory variable at each point is selected by the classification and regression tree algorithm. The groups were defined by the observed incidence of relapse within each node of the graph for deleted and nondeleted cases, respectively. Relapse risk ratio (RR) and lower-level CIs (LL) are presented. het, heterozygous; hom, homozygous.



**Fig A3.** Cumulative relapse incidence (CIR) at five years in B-cell precursor ALL patients treated on trial AIEOP-BFM (Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin–Frankfurt–Muenster) ALL 2000 according to *IKZF1* status alone or in combination with (A) heterozygous or homozygous *ETV6* deletion, (B) heterozygous or homozygous *RB1* deletion, (C) heterozygous or homozygous *BTG1* deletion, (D) heterozygous or homozygous *EBF1* deletion. pCIR, estimated cumulative incidence of relapse. del, deletion; het, heterozygous; hom, homozygous.





**Fig A4.** Cumulative relapse incidence (CIR) at five years in B-cell precursor ALL patients treated on trial AIEOP-BFM (Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster) ALL 2000 stratified by white blood cell (WBC) count and NCI risk groups according to *IKZF1* status (no *IKZF1* deletion, *IKZF1*-deleted, *IKZF1*<sup>plus</sup>). NCI standard-risk patients were one to younger than ten years and had an initial WBC count of < 50,000/ $\mu$ l, NCI high-risk patients were ten years and older and/or had an initial WBC of  $\geq$  50,000/ $\mu$ l. CIR in (A) NCI standard-risk patients, (B) NCI high-risk patients, (C) patients with initial WBC counts  $\geq$  50,000/ $\mu$ l, and (D) patients with initial WBC counts of  $\geq$  100,000/ $\mu$ l. pCIR, estimated cumulative incidence of relapse. del, deletion.

**Table A1.** Deletion Matrix for 991 German Patients With B-Cell Precursor ALL Treated in Trial AIEOP-BFM ALL 2000

Deletion Combination*	No <i>IKZF1</i> del		<i>IKZF1</i> del†		<i>IKZF1</i> <sup>plus‡</sup>
	<i>ERG</i> del Negative	<i>ERG</i> del Positive	<i>ERG</i> del Negative	<i>ERG</i> del Positive	
<i>CDKN2A</i> wild type					
<i>PAX5</i> wild type					
<i>CDKN2B</i> wild type					
PAR1 wild type	516	22	57	19	
PAR1 del	4	—	—	—	9
<i>CDKN2B</i> het del					
PAR1 wild type	5	—	1	1	
<i>CDKN2B</i> hom del					
PAR1 wild type	2	—			
<i>PAX5</i> het or hom del					
<i>CDKN2B</i> wild type					
PAR1 wild type	65	3		1	9
PAR1 del	3	—		—	2
<i>CDKN2B</i> hom del					
PAR1 wild type	1	—			
<i>CDKN2A</i> het del					
<i>PAX5</i> wild type					
<i>CDKN2B</i> wild type					
PAR1 wild type	12	1			2
PAR1 del	1	—			
<i>CDKN2B</i> het del					
PAR1 wild type	53	2		1	5
PAR1 del	1	—			
<i>CDKN2B</i> hom del					
PAR1 wild type	8	—			2
PAR1 del	1	—			
<i>PAX5</i> het or hom del					
<i>CDKN2B</i> wild type					
PAR1 wild type	2	—			1
<i>CDKN2B</i> het del					
PAR1 wild type	22	3		2	4
PAR1 del	1	—			2
<i>CDKN2B</i> hom del					
PAR1 wild type	8	—			2
PAR1 del	2	—			1
<i>CDKN2A</i> hom del					
<i>PAX5</i> wild type					
<i>CDKN2B</i> wild type					
PAR1 wild type	1	—			
PAR1 del	1	—			
<i>CDKN2B</i> het del					
PAR1 wild type	6	1			3
PAR1 del	—	—			1
<i>CDKN2B</i> hom del					
PAR1 wild type	39	1			7
PAR1 del	3	—			
<i>PAX5</i> het or hom del					
<i>CDKN2B</i> wild type					
PAR1 wild type	2	—			
<i>CDKN2B</i> het del					
PAR1 wild type	10	—			5
PAR1 del	2	—			
<i>CDKN2B</i> hom del					
PAR1 wild type	38	—		1	8
PAR1 del	3	—			

Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; del, deletion; het, heterozygous; hom, homozygous.

\*On the basis of multiplex ligation-dependent probe amplification analysis for *IKZF1*, *CDKN2A*, *PAX5*, *CDKN2B*, and PAR1 according to genomic polymerase chain reaction for *ERG*.

†*IKZF1* del present but does not fulfill the *IKZF1*<sup>plus</sup> definition.

‡Presence of *IKZF1* del and at least an additional deletion in *PAX5*, *CDKN2A*, *CDKN2B*, or PAR1 in the absence of *ERG* del.

**Table A2.** Clinical Characteristics According to *IKZF1* Status in 417 Italian Patients With Precursor B-Cell ALL Treated in Trial AIEOP-BFM ALL 2000

Characteristic	<i>IKZF1</i> Status, No. (%)			P*
	No <i>IKZF1</i> Deletion	<i>IKZF1</i> Deletion	<i>IKZF1</i> <sup>plus</sup>	
No. of patients	357	42	18	
Sex				
Male	188 (52.7)	22 (52.4)	8 (44.4)	
Female	169 (47.3)	20 (47.6)	10 (55.6)	.793
Age at diagnosis, years				
< 10	307 (86.0)	28 (66.7)	12 (66.7)	
≥ 10	50 (14.0)	14 (33.3)	6 (33.3)	.001
Presenting WBC, count/ $\mu$ L				
< 10,000	199 (55.7)	18 (42.9)	5 (27.8)	
10,000 to < 50,000	111 (31.1)	18 (42.9)	5 (27.8)	
50,000 to < 100,000	23 (6.4)	2 (4.8)	5 (27.8)	
≥ 100,000	24 (6.7)	4 (9.5)	3 (16.7)	< .001
CNS disease†				
Negative	357 (100)	42 (100)	18 (100)	—
Positive	—	—	—	
Other/unknown	—	—	—	
Hyperdiploidy‡				
No	251 (70.3)	33 (78.6)	17 (94.4)	
Yes	81 (22.7)	5 (11.9)	—	.023
Unknown	25 (7.0)	4 (9.5)	1 (5.6)	
<i>ETV6-RUNX1</i>				
Negative	257 (72.0)	38 (90.5)	17 (94.4)	
Positive	82 (23.0)	—	1 (5.6)	< .001
Unknown	18 (5.0)	4 (9.5)	—	
<i>MLL-AF4</i>				
Negative	352 (98.6)	42 (100)	18 (100)	
Positive	3 (0.8)	—	—	.775
Unknown	2 (0.6)	—	—	
Prednisone response§				
Good	333 (93.3)	39 (92.9)	17 (94.4)	
Poor	21 (5.9)	3 (7.1)	—	.550
Unknown	3 (0.8)	—	1 (5.6)	
MRD				
TP1 and TP2 negative	116 (32.5)	5 (11.9)	3 (16.7)	
Other	162 (45.4)	20 (47.6)	8 (44.4)	
TP2 ≥ 10 <sup>-3</sup>	3 (0.8)	6 (14.3)	—	< .001
Unknown	76 (21.3)	11 (26.2)	7 (38.9)	
Final risk group¶				
SR	109 (30.5)	5 (11.9)	3 (16.7)	
IR	222 (62.2)	30 (71.4)	12 (66.7)	
HR	26 (7.3)	7 (16.7)	3 (16.7)	< .001

NOTE. *IKZF1*<sup>plus</sup> definition: presence of *IKZF1* deletion and at least an additional deletion in *PAX5*, *CDKN2A*, *CDKN2B*, or *PAR1* in the absence of *ERG* deletion. *IKZF1* deletion definition: *IKZF1* deletion present but does not fulfill the *IKZF1*<sup>plus</sup> definition.

Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; HR, high risk; IR, intermediate risk; MRD, minimal residual disease; SR, standard risk; TP, time point.

\* $\chi^2$  or Fisher's exact test that compares the groups with various *IKZF1* statuses.

†CNS negative, puncture nontraumatic without leukemic blasts in the CSF after cytocentrifugation; CNS positive, puncture nontraumatic with WBC > 5/ $\mu$ L in the CSF with identifiable blasts.

‡Defined by cytogenetics (> 50 chromosomes) or by flow cytometric analyses of the ratio of DNA content of leukemic G0/G1 cells to normal diploid lymphocytes (≥ 1.16).

§Good, < 1,000 leukemic blood blasts/ $\mu$ L on treatment day 8; poor, ≥ 1,000/ $\mu$ L.

||TP1, treatment day 33; TP2, treatment day 78; MRD ≥ 10<sup>-3</sup> qualifies for the MRD-HR group.

¶For definition of risks, see Patients and Methods, under Sample Selection.

**Table A3.** Estimated HRs From the Multivariable Cox Proportional Hazards Model on Event-Free Survival and Hazard of Relapse in Patients With B-Cell Precursor ALL in Trial AIEOP-BFM ALL 2000

Variable	Event			Relapse		
	HR	95% CI	P	HR	95% CI	P
<i>IKZF1</i> <sup>plus</sup> *	2.95	1.02 to 8.55	.046	3.16	1.08 to 9.28	.036
<i>IKZF1</i> deletion†	0.85	0.38 to 1.88	.688	0.84	0.37 to 1.90	.681
<i>ETV6-RUNX1</i> positivity‡	2.26	0.95 to 5.34	.064	2.12	0.89 to 5.05	.088
MRD standard risk§	0.34	0.16 to 0.71	.004	0.36	0.17 to 0.76	.004
MRD high risk§	23.49	6.82 to 80.85	< .001	33.53	9.67 to 116.30	.018
Slow early MRD response	2.08	1.08 to 4.02	.029	2.22	1.14 to 4.31	.018
Poor prednisone response¶	0.40	0.10 to 1.56	.186	0.29	0.06 to 1.31	.107
Presenting WBC# count ≥ 100,000/μL	1.18	0.40 to 3.43	.767	1.07	0.34 to 3.36	.907

Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; HR, hazard ratio; MRD, minimal residual disease.

\*Presence of *IKZF1* deletion and at least an additional deletion in *PAX5*, *CDKN2A*, *CDKN2B*, or *PAR1* in the absence of *ERG* deletion. HR compared with patients who lacked an *IKZF1* deletion.

†*IKZF1* deletion present but does not fulfill the *IKZF1*<sup>plus</sup> definition. HR compared with patients who lacked an *IKZF1* deletion.

‡HR compared with *ETV6-RUNX1* negative.

§MRD standard risk, negative on treatment days 33 and 78; MRD high risk, leukemic cell load ≥ 5 × 10<sup>-4</sup> on treatment day 78; all other results MRD intermediate risk. HR compared with other MRD groups.

||MRD ≥ 5 × 10<sup>-4</sup> on treatment day 33 and positivity of < 5 × 10<sup>-4</sup> on treatment day 78. HR compared with MRD intermediate risk patients with no slow early response.

¶Leukemic blasts ≥ 1,000/μL in the peripheral blood on treatment day 8. HR compared with patients with < 1,000/μL leukemic blasts.

#HR compared with patients with presenting WBC counts < 100,000/μL.

**Table A4.** Deletions in *IKZF1*<sup>plus</sup> Patients in Trial AIEOP-BFM ALL 2000 by Various MRD Groups

Type of Deletion	MRD Group*, No. (%)			
	SR	IR	HR	Unknown
No. of patients	19	27	10	7
<i>CDKN2A</i> wild type	5 (26.3)	9 (33.3)	3 (30.0)	3 (42.9)
<i>CDKN2A</i> het or hom del	14 (73.7)	18 (66.6)	7 (70.0)	4 (57.1)
<i>PAX5</i> wild type	6 (31.6)	11 (40.7)	7 (70.0)	5 (71.4)
<i>PAX5</i> het or hom del	13 (68.4)	16 (59.3)	3 (30.0)	2 (28.6)
<i>CDKN2B</i> wild type or het del	12 (63.2)	19 (70.4)	6 (60.0)	6 (85.7)
<i>CDKN2B</i> hom del	7 (36.8)	8 (29.6)	4 (40.0)	1 (14.3)
<i>PAR1</i> wild type	15 (78.9)	20 (74.1)	9 (90.0)	5 (71.4)
<i>PAR1</i> del	4 (21.1)	7 (25.9)	2 (20.0)	2 (28.6)

NOTE. On the basis of a multiplex ligation-dependent probe amplification analysis. *IKZF1*<sup>plus</sup> definition: presence of *IKZF1* deletion and at least an additional deletion in *PAX5* (het or hom), *CDKN2A* (het or hom), *CDKN2B* (hom only), or *PAR1* (het or hom) in the absence of *ERG* deletion (het or hom).

Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; del, deletion; het, heterozygous; hom, homozygous; HR, high risk; IR, intermediate risk; MRD, minimal residual disease; SR, standard risk.

\*MRD-SR, negative on treatment days 33 and 78; MRD-HR, leukemic cell load ≥ 5 × 10<sup>-4</sup> on treatment day 78; all other results MRD-IR.

**Table A5.** Number of Unfavorable Deletions in Addition to *IKZF1* in *IKZF1<sup>plus</sup>* Patients in Trial AIEOP-BFM ALL 2000 by Various MRD Groups

No. of deletions	MRD Group*, No. (%)			
	SR	IR	HR	Unknown
No. of patients	19	27	10	7
One deletion	6 (31.6)	12 (44.4)	5 (50.0)	5 (71.4)
Two deletions	7 (36.8)	9 (33.3)	4 (40.0)	2 (28.6)
Three deletions	6 (31.6)	5 (18.5)	1 (10.0)	—
Four deletions	—	1 (3.7)	—	—

NOTE. On the basis of a multiplex ligation-dependent probe amplification analysis, including *CDKN2A*, *PAX5*, *CDKN2B*, and *PAR1*. *IKZF1<sup>plus</sup>* definition: presence of *IKZF1* deletion and at least an additional deletion in *PAX5* (het or hom), *CDKN2A* (het or hom), *CDKN2B* (hom only), or *PAR1* (het or hom) in the absence of *ERG* deletion (het or hom). Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; het, heterozygous; hom, homozygous; HR, high risk; IR, intermediate risk; MRD, minimal residual disease; SR, standard risk.

\*MRD-SR, negative on treatment days 33 and 78; MRD-HR, leukemic cell load  $\geq 5 \times 10^{-4}$  on treatment day 78; all other results MRD-IR. *P* = .750 by  $\chi^2$  test for comparison of the various MRD groups for differences in number of deletions.

**Table A6.** Genes Affected in Deletion Patterns at Initial Diagnosis and at Relapse in 14 *IKZF1<sup>plus</sup>* Patients

Sample Pair	Initial Diagnosis	Relapse Diagnosis
1	<i>IKZF1</i> het, <i>PAX5</i> het	<i>IKZF1</i> het, <i>CDKN2A</i> het, <i>CDKN2B</i> het, <i>PAX5</i> het
2	<i>IKZF1</i> het, <i>CDKN2A</i> hom, <i>CDKN2B</i> hom, <i>PAX5</i> het	<i>IKZF1</i> het, <i>CDKN2A</i> het, <i>CDKN2B</i> het
3	<i>IKZF1</i> het, <i>PAX5</i> het	<i>IKZF1</i> het, <i>PAX5</i> het
4	<i>IKZF1</i> het, <i>PAR1</i> het	<i>IKZF1</i> het
5	<i>IKZF1</i> het, <i>PAR1</i> het	<i>IKZF1</i> het
6	<i>IKZF1</i> het, <i>PAX5</i> het	<i>IKZF1</i> het, <i>CDKN2A</i> het, <i>CDKN2B</i> hom, <i>PAX5</i> hom
7	<i>IKZF1</i> het, <i>CDKN2A</i> hom, <i>CDKN2B</i> het, <i>PAX5</i> het	<i>IKZF1</i> het, <i>CDKN2A</i> hom, <i>CDKN2B</i> het, <i>PAX5</i> het
8	<i>IKZF1</i> hom, <i>CDKN2A</i> hom, <i>CDKN2B</i> hom	<i>IKZF1</i> hom, <i>CDKN2A</i> hom, <i>CDKN2B</i> hom
9	<i>IKZF1</i> het, <i>PAX5</i> het	<i>IKZF1</i> het, <i>PAX5</i> het
10	<i>IKZF1</i> het, <i>PAR1</i> het	<i>IKZF1</i> het, <i>PAR1</i> het
11	<i>IKZF1</i> het, <i>CDKN2A</i> het, <i>CDKN2B</i> hom, <i>PAX5</i> het	<i>IKZF1</i> het, <i>CDKN2A</i> het, <i>CDKN2B</i> hom, <i>PAX5</i> het
12	<i>IKZF1</i> het, <i>CDKN2A</i> hom, <i>CDKN2B</i> het	<i>IKZF1</i> het, <i>CDKN2A</i> het, <i>CDKN2B</i> het
13	<i>IKZF1</i> het, <i>CDKN2A</i> het, <i>CDKN2B</i> hom, <i>PAX5</i> hom, <i>PAR1</i> het	<i>IKZF1</i> het, <i>CDKN2A</i> het, <i>CDKN2B</i> hom, <i>PAX5</i> hom, <i>PAR1</i> het
14	<i>IKZF1</i> het, <i>PAX5</i> het	<i>IKZF1</i> het, <i>PAX5</i> het

NOTE. On the basis of a multiplex ligation-dependent probe amplification analysis, including *CDKN2A*, *PAX5*, *CDKN2B*, and *PAR1*. *IKZF1<sup>plus</sup>* definition: presence of *IKZF1* deletion and at least an additional deletion in *PAX5* (het or hom), *CDKN2A* (het or hom), *CDKN2B* (hom only), or *PAR1* (het or hom) in the absence of *ERG* deletion (het or hom).

Abbreviations: het, heterozygous; hom, homozygous.